Search

Your search keyword '"Barranco, E"' showing total 113 results

Search Constraints

Start Over You searched for: Author "Barranco, E" Remove constraint Author: "Barranco, E"
113 results on '"Barranco, E"'

Search Results

4. Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: Results from the CREDENCE trial and meta-analysis

5. Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis

11. The Gulf of Cadiz: an unstable giant contouritic levee

13. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

17. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From the Randomized CREDENCE Trial

18. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics

21. Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease

22. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3

23. The 'Shackleton Site' (IODP Site U1385) on the Iberian Margin

24. Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes

25. 211 SPANISH REGISTRY OF ERYTHROPOIETIC STIMULATING AGENTS STUDY: THE LARGEST RETROSPECTIVE STUDY OF ESAS FOR THE TREATMENT OF ANEMIA IN LOWER RISK MDS PATIENTS

28. The 'Shackleton Site' (IODP Site U1385) on the Iberian Margin

30. 1530 – Suicide, religion and holy week

33. Past deep-ocean circulation and the paleoclimate record-Gulf of Cadiz

37. Environmental significance of the Mediterranean Outflow Water and its global implications

38. SPRESAS (SPANISH REGISTRY OF ERYTHROPOIETIC STIMULATING AGENTS STUDY) SUBANALYSIS: IMPACT OF COMORBIDITIES AND CENTER LEVEL ON RESPONSE TO ESAS IN LOWER RISK MDS

39. Reclassification after delivery of diabetes in pregnancy

40. SPRESAS (SPANISH REGISTRY OF ERYTHROPOIETIC STIMULATING AGENTS STUDY): THE LARGEST RETROSPECTIVE STUDY OF TREATMENT WITH ESAS IN LOWER RISK MDS

42. Sporadic Creutzfeldt-Jakob disease VM1: phenotypic and molecular characterization of a novel subtype of human prion disease

43. Prevalence of SARS-CoV-2 Infection among Children and Adults in 15 US Communities, 2021

44. The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials.

45. Phase I Trial of a Therapeutic DNA Vaccine for Preventing Hepatocellular Carcinoma from Chronic Hepatitis C Virus (HCV) Infection.

46. Sporadic Creutzfeldt-Jakob disease VM1: phenotypic and molecular characterization of a novel subtype of human prion disease.

47. Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor.

49. [Pharmacological treatment of dementia: when, how and for how long. Recommendations of the Working Group on Dementia of the Catalan Society of Geriatrics and Gerontology].

50. [Informing of the diagnosis in dementia].

Catalog

Books, media, physical & digital resources